Document is current
Any future updates will be listed below
-
Authors
Solana-Altabella, Antonio https://orcid.org/0000-0002-8804-3878
Iniesta-Navalón, Carles https://orcid.org/0000-0002-3950-7250
Chovi-Trull, Maria https://orcid.org/0009-0000-3169-5253
Rodriguez-Veiga, Rebeca
Lopez-Nogueroles, Marina https://orcid.org/0000-0003-3114-2231
Martínez-Cuadrón, David https://orcid.org/0000-0001-7540-4091
Gil-Candel, Mayte https://orcid.org/0000-0002-7398-8350
Torres-Miñana, Laura
Acuña-Cruz, Evelyn
Cano-Ferri, Isabel
Boluda, Blanca https://orcid.org/0000-0002-1785-5561
Navarro-Vicente, Irene
Lloret-Madrid, Pilar
Barragán, Eva
Gil, Jose Vicente https://orcid.org/0000-0003-2097-4796
Rodenas-Rovira, Mario https://orcid.org/0000-0003-2256-3595
Megías-Vericat, Juan Eduardo https://orcid.org/0000-0002-0369-5341
Labrador, Jorge https://orcid.org/0000-0002-3696-0287
Peris-Ribera, José Esteban https://orcid.org/0000-0002-4811-239X
Poveda-Andrés, Jose Luis https://orcid.org/0000-0003-1800-6198
Montesinos, Pau https://orcid.org/0000-0002-3275-5593
-
Funding
Funding for this research was provided by:
Fundación Española de Farmacia Hospitalaria (2022-829-1)
Instituto de Salud Carlos III (CM23/00148)
Fundación para la Investigación del Hospital Universitari La Fe (2023-432-1)
PETHEMA foundation (2020-017-1)
Universitat de Valencia
- License Information
-
More Information
Article History
Received: 19 February 2025
Accepted: 16 August 2025
First Online: 30 August 2025
Declarations
: Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of Instituto de Investigación Sanitaria La Fe (IISLAFE) of Valencia (protocol code 2020–017-1, and date of approval 11th March 2020).Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
: PM reports the following potential conflicts of interest. AbbVie: advisory board, speakers bureau, research support; Astellas: research support, consultant, speakers bureau, advisory board; Agios: consultant; Tolero Pharmaceutical: consultant; Glycomimetics: consultant; Forma Therapeutics: consultant; Celgene: research support, consultant, speakers bureau, advisory board; Daiichi Sankyo: research support, consultant, speakers bureau, advisory board; Incyte: speakers bureau, advisory board; Janssen: research support, speakers bureau, advisory board; Karyopharm: research support, advisory board; Novartis: research support, speakers bureau, advisory board; Pfizer: research support, speakers bureau, advisory board; Teva: research support, speakers bureau, advisory board. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
